Alginate hydrogel improves anti-angiogenic bevacizumab activity in cancer therapy

October 11, 2018


Alginate hydrogel improves anti-angiogenic bevacizumab activity in cancer therapy


Natália N. Ferreira, Leonardo M. B. Ferreira, Vera Miranda-Gonçalves, Rui M. Reis, Thiago V. Seraphim, Júlio CésarBorges, Fátima Baltazar, Maria Palmira D. Gremião




European Journal of Pharmaceutics and Biopharmaceutics


Anti-vascular endothelial growth factor (anti-VEGF) therapy applied to solid tumors is a promising strategy, yet, the challenge to deliver these agents at high drug concentrations together with the maintenance of therapeutic doses locally, at the tumor site, minimizes its benefits. To overcome these obstacles, we propose the development of a bevacizumab-loaded alginate hydrogel by electrostatic interactions to design a delivery system for controlled and anti-angiogenic therapy under tumor microenvironmental conditions. The tridimensional hydrogel structure produced provides drug stability and a system able to be introduced as a flowable solution, stablishing a depot after local administration. Biological performance by the chick embryo chorioallantoic membrane (CAM) assay indicated a pH-independent improved anti-angiogenic activity (∼50%) compared to commercial available anti-VEGF drug. Moreover, there was a considerable regression in tumor size when treated with this system. Immunohistochemistry highlighted a reduced number and disorganization of microscopic blood vessels resulting from applied therapy. These results suggest that the developed hydrogel is a promising approach to create an innovative delivery system that offers the possibility to treat different solid tumors by intratumoral administration.




Circular dichroism, Secondary structure, Chemical stability, Biochemistry